about
Role of MGMT as biomarker in colorectal cancer.Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.Clinical implications for pro-GRP in small cell lung cancer. A single center experience."Systemic strategy at the patient's service": a congress report on supportive care in oncology.Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramTemozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationBilateral parotid gland metastases from gastric signet-ring cell carcinomaGenomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategiesSecond-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyPerioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver MetastasesIs a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trialCombination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective AnalysisIs There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer PatientsSomatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETsLack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous ComponentComparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-AnalysisTargeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
P50
Q34706115-6C65ED71-C9AF-4F88-A50B-35A5BF9EF2E6Q39011428-145FFC0D-2964-4EB2-B0FC-6492EDBFEF22Q47887846-2120349C-56DB-45D7-A57D-297BDF6754A9Q48703626-CB8B3799-7701-48C0-ABAD-FEEBEC046EB1Q51747406-70962648-F598-4D79-A07F-70234FA93ADFQ52587886-A5BCD2E6-42B0-4F7D-AC75-668323496DC7Q53142866-F99AB2EC-D188-47E0-BB62-8013E5B7591EQ55689035-9E91272B-D28D-4014-8BE4-97FABA583FC2Q64930981-D2A64590-ED7B-4052-A653-7E3B3CF4A0F5Q88608605-CBA25B62-D932-4AD0-8955-F33D703EBC38Q88961041-4630561B-3C71-4C6E-BB43-30FEA01CC8C4Q89446943-985BD3C0-EBFB-4685-BCA6-2B305DCDCEE4Q90447504-5541BD21-2FE0-4041-9672-E51614A97841Q90520295-4386FA76-58D4-425E-AFD6-DF442E917901Q90592695-EFDD74EE-83B2-471D-93E3-5A15A2E5253BQ91322925-63AF65E9-7D0E-4B7E-843C-30E37614107BQ92086321-BA0C0019-BA5B-4325-8146-6257FAA02FB9Q92144236-768F394B-F57F-4412-A210-B7050FAF833AQ92282260-FE2350A2-5136-4F89-8EB9-099125AADFE6Q92691043-5CDD9D12-AA6D-44DE-A182-841E4499BAA6Q92883841-728D8F3D-AFC0-45F8-B995-9A0EC255F24BQ92934281-24896F16-B888-4439-ADB4-207A41B33E15Q93374158-B90AD62F-3C16-4DB6-B55C-3FDD2A3B1981
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Federico Nichetti
@ast
Federico Nichetti
@en
Federico Nichetti
@es
Federico Nichetti
@nl
Federico Nichetti
@sl
type
label
Federico Nichetti
@ast
Federico Nichetti
@en
Federico Nichetti
@es
Federico Nichetti
@nl
Federico Nichetti
@sl
prefLabel
Federico Nichetti
@ast
Federico Nichetti
@en
Federico Nichetti
@es
Federico Nichetti
@nl
Federico Nichetti
@sl
P106
P21
P31
P496
0000-0001-8044-4207
P569
2000-01-01T00:00:00Z